panflu Stats Forum Indexpanflu Stats
Influenza Pandemic Science, Statistics and News
 
 FAQFAQ   SearchSearch   MemberlistMemberlist   UsergroupsUsergroups   RegisterRegister 
 ProfileProfile   Log in to check your private messagesLog in to check your private messages   Log inLog in            Calendar

NEWS:
Report on BioVant's Adjuvanted Vaccine

 
Post new topic   Reply to topic    panflu Stats Forum Index -> Vaccine Development
View previous topic :: View next topic  
Author Message
Mixin



Joined: 15 Dec 2007
Posts: 1419
:


Items

PostPosted: Wed Aug 19, 2009 8:13 am    Post subject: Report on BioVant's Adjuvanted Vaccine Reply with quote

This is part of a press release from the Vax Summit
-------------------------------------------------------------

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced today's presentation of H1N1 vaccine results at the Immunotherapeutics & Vaccine Summit in Providence, RI. BioSante's vaccine adjuvant, BioVant increased the protective effect of vaccines for multiple flu strains, including a potential new vaccine against H1N1 (swine flu), which resulted in 100 percent protection from symptoms of illness, including weight loss, and death in animal studies.

The BioSante presentation, "BioVant Calcium Phosphate (CaP) Nanoparticles: An Effective & Safe Adjuvant for Influenza Vaccines including H1N1 and H5N1," showed that BioVant-adjuvant effectively enhanced the natural immune response to the swine flu, using a BioVant-adjuvanted matrix protein M1 vaccine, and to H5N1 (bird flu), using a BioVant-adjuvanted H5N1 vaccine delivered via intranasal administration.

The studies concluded that swine and bird flu vaccines using BioSante's BioVant may allow for availability of a greater number of lower-dose vaccines, due to its dose sparing characteristics, and intranasal administration could provide more convenient and wider distribution during a flu pandemic.

The results of the BioVant-influenza studies suggest that BioVant can increase the efficacy of a potential adjuvant-enhanced H1N1 vaccine, said Michael Snabes, BioSante's vice president of clinical development. The exciting prospect is that BioVant also may allow use of lower doses of H1N1 swine flu vaccines in order to stretch potentially limited vaccine supplies.

http://www.genengnews.com/news/bnitem.aspx?name=60699839
_________________
https://twitter.com/mixin1771
Back to top
View user's profile Send private message
Display posts from previous:   
Post new topic   Reply to topic    panflu Stats Forum Index -> Vaccine Development All times are GMT
Page 1 of 1

 
Jump to:  
You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot vote in polls in this forum
panflu Stats topic RSS feed 


Powered by phpBB © 2001, 2005 phpBB Group
FREE FORUM HOSTING by AtFreeForum. Terms of Service - Privacy Policy
FASHION ACCESSORIES - BLING BLING - LADIES WATCHES - KOREAN CHILDREN CLOTHING - ONLINE BARGAIN STORE - FASHION JEWELLERIES